Coherus Oncology (CHRS) Common Equity (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Common Equity data on file, last reported at $78.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 142.85% year-over-year to $78.6 million; the trailing twelve-month figure through Mar 2026 stood at $78.6 million (up 142.85% YoY), and the FY2025 full-year result was $61.0 million, up 146.23% from the prior year.
• Common Equity grew to $78.6 million in Q1 2026, from $61.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $119.8 million in Q2 2025 to a low of -$196.5 million in Q1 2023.
• A 5-year average of -$68.5 million and a median of -$88.0 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 1664.17% in 2023 and surged 242.47% in 2025, its largest moves.
• Tracing CHRS's Common Equity over 5 years: stood at -$137.4 million in 2022, then tumbled by 40.76% to -$193.4 million in 2023, then surged by 31.76% to -$132.0 million in 2024, then jumped by 146.23% to $61.0 million in 2025, then rose by 28.86% to $78.6 million in 2026.
• Business Quant data shows CHRS's Common Equity at $78.6 million in Q1 2026, $61.0 million in Q4 2025, and $87.8 million in Q3 2025.